BUSINESS● LOW2h ago · Oct 23, 2026, 9:05 PM
Corcept Therapeutics plunges 20% on Genmab cancer data
Seeking Alpha Tech · global
Corcept Therapeutics experienced a 20% stock drop following the release of cancer data from Genmab. This financial event indicates market reaction to new medical research affecting pharmaceutical companies.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS27m agoAbelardo claims victory for the purchase of Nutresa by PrestoLa Silla VacíaBUSINESS42m agoMoody's holds steady on France's credit rating as country grapples with turmoil and higher yieldsCNBC